Overdiagnosis and Overtreatment in Prostate Cancer DOI Creative Commons
Zaure Dushimova, Yerbolat Iztleuov, Gulnar Chingayeva

и другие.

Diseases, Год журнала: 2025, Номер 13(6), С. 167 - 167

Опубликована: Май 24, 2025

Prostate cancer (PCa) is one of the most common malignancies among men worldwide. While prostate-specific antigen (PSA) screening has improved early detection, it also led to significant challenges regarding overdiagnosis and overtreatment. Overdiagnosis involves identifying indolent tumors unlikely affect a patient’s lifespan, while overtreatment refers unnecessary interventions that can cause adverse effects such as urinary incontinence, erectile dysfunction, reduced quality life. This review highlights contributing factors, including limitations PSA testing, advanced imaging techniques like multi-parametric MRI (mpMRI), medical culture, patient expectations. The analysis emphasizes need for refining protocols, integrating novel biomarkers (e.g., PCA3, TMPRSS2-ERG), adopting conservative management strategies active surveillance minimize harm. Risk-based shared decision-making are critical balancing benefits detection with risks treatment. Additionally, systemic healthcare factors financial incentives malpractice concerns exacerbate overuse. advocates updated clinical guidelines personalized approaches optimizing outcomes reducing strain on resources. Addressing through targeted will improve life PCa patients enhance efficiency systems.

Язык: Английский

PSMA-targeted Biopsy with Fusion Guidance for Detecting Clinically Significant Prostate Cancer in Men with Negative MRI – Feasibility and Diagnostic Performance of a Pilot Single-Center Prospective Study DOI

Lorenzo Bianchi,

Danilo Cangemi,

Andrea Farolfi

и другие.

Clinical Genitourinary Cancer, Год журнала: 2025, Номер unknown, С. 102348 - 102348

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

1
Overdiagnosis and Overtreatment in Prostate Cancer DOI Creative Commons
Zaure Dushimova, Yerbolat Iztleuov, Gulnar Chingayeva

и другие.

Diseases, Год журнала: 2025, Номер 13(6), С. 167 - 167

Опубликована: Май 24, 2025

Prostate cancer (PCa) is one of the most common malignancies among men worldwide. While prostate-specific antigen (PSA) screening has improved early detection, it also led to significant challenges regarding overdiagnosis and overtreatment. Overdiagnosis involves identifying indolent tumors unlikely affect a patient’s lifespan, while overtreatment refers unnecessary interventions that can cause adverse effects such as urinary incontinence, erectile dysfunction, reduced quality life. This review highlights contributing factors, including limitations PSA testing, advanced imaging techniques like multi-parametric MRI (mpMRI), medical culture, patient expectations. The analysis emphasizes need for refining protocols, integrating novel biomarkers (e.g., PCA3, TMPRSS2-ERG), adopting conservative management strategies active surveillance minimize harm. Risk-based shared decision-making are critical balancing benefits detection with risks treatment. Additionally, systemic healthcare factors financial incentives malpractice concerns exacerbate overuse. advocates updated clinical guidelines personalized approaches optimizing outcomes reducing strain on resources. Addressing through targeted will improve life PCa patients enhance efficiency systems.

Язык: Английский

Процитировано

0